Related Experiment Video
Updated: Feb 11, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating
Shuai Liu1, Yongfeng Lao1, Long Cheng1
1Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Abstract:
Docetaxel (DTX) resistance is the main cause of treatment failure in castration-resistant prostate cancer (CRPC). Pyrroline-5-carboxylic acid reductase 1 (PYCR1) is an enzyme involved in proline metabolism. It is highly expressed in various cancers and promotes malignant progression, yet its role in DTX resistance in prostate cancer remains unclear. In this study, bioinformatics analyses and in vitro/vivo experiments demonstrated that interfering with PYCR1 expression modulates the sensitivity of prostate cancer cells to DTX. Subsequently, via structure-based virtual screening, molecular dynamics simulations, and cellular thermal shift assay (CETSA), emodin-an anthraquinone compound-was identified as a PYCR1-targeting agent. Collectively, these findings suggest that PYCR1 may serve as a key target mediating DTX resistance in prostate cancer, and the emodin-DTX combination provides a promising potential clinical strategy to overcome such resistance. Finally, its functions and safety were also verified through in vitro experiments.
Insights
Pyrroline-5-carboxylic acid reductase 1 (PYCR1) drives docetaxel resistance in prostate cancer. Targeting PYCR1 with emodin may overcome this resistance, offering a new clinical strategy for castration-resistant prostate cancer (CRPC) treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Docetaxel (DTX) resistance is a major challenge in treating castration-resistant prostate cancer (CRPC).
- Pyrroline-5-carboxylic acid reductase 1 (PYCR1), involved in proline metabolism, is upregulated in cancers but its role in DTX resistance in prostate cancer is unknown.
Purpose of the Study:
- To investigate the role of PYCR1 in DTX resistance in prostate cancer.
- To identify potential therapeutic agents targeting PYCR1 to overcome DTX resistance.
Main Methods:
- Bioinformatics analyses, in vitro/vivo experiments to assess PYCR1's role.
- Structure-based virtual screening, molecular dynamics simulations, and CETSA to identify PYCR1 inhibitors.
- In vitro experiments to verify safety and efficacy of identified agents.
Main Results:
- Interfering with PYCR1 expression altered prostate cancer cell sensitivity to DTX.
- Emodin was identified as a PYCR1-targeting agent.
- The combination of emodin and DTX showed potential in overcoming resistance.
Conclusions:
- PYCR1 is a key mediator of DTX resistance in prostate cancer.
- Emodin-DTX combination therapy presents a promising strategy for CRPC treatment.
- Further studies confirmed the functions and safety of emodin.
Related Concept Videos
Molecular Models
Virtual Work
In static equilibrium, a body can experience an imaginary or virtual movement, such as displacement or rotation. The virtual work done by a force is equal to the dot product of force and virtual displacement in the direction of the force. When it comes to virtually rotating a...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Dynamic Equilibrium
Principle of Virtual Work: Problem Solving
To apply the principle of virtual work,...
Integration by Parts: Indefinite Integrals

